Your insurance said no.
We'll help you fight it.

How to Fight Insurance Denials for GLP-1 Weight-Loss Medications

GLP-1 receptor agonists—including Wegovy, Zepbound, Mounjaro, Ozempic, and Saxenda—are among the most effective obesity treatments available, with clinical trials showing 10–22% total body weight loss and improvement in diabetes, blood pressure, sleep apnea, and cardiovascular outcomes. They are also among the most inconsistently covered. The clearest example: in 2024, Ozempic (semaglutide, labeled for type 2 diabetes) was covered by roughly 82% of ACA Marketplace plans, while Wegovy—the same molecule, labeled for weight loss—was covered by only about 1%, and every plan that did cover it required prior authorization (KFF, 2024). Whether your GLP-1 is paid for often turns less on your health than on which label is on the box. This guide walks you through the most common denial reasons, the clinical guidelines and trial data insurers are bound to respect, and the specific counter-arguments that work.

The Same Molecule, Two Prices

Most GLP-1s are sold under two brand names with two different FDA labels — one approved for type 2 diabetes (which insurers cover broadly) and one approved for weight management (which they widely exclude) — even though the drug inside is identical:

• Semaglutide — Ozempic and Rybelsus (type 2 diabetes) vs. Wegovy (weight management)
• Tirzepatide — Mounjaro (type 2 diabetes) vs. Zepbound (weight management)
• Liraglutide — Victoza (type 2 diabetes) vs. Saxenda (weight management)

This is the single most useful thing to understand about a GLP-1 denial. If you have — or develop — a covered, non-weight-loss FDA indication, your prescriber can often redirect both the prescription and the appeal to that indication:

• Type 2 diabetes → the diabetes-labeled product (Ozempic, Mounjaro) is covered on the standard pharmacy benefit.
• Established cardiovascular disease → Wegovy gained an FDA indication in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with known heart disease who are overweight or obese — the first weight-management drug with a cardiovascular indication.
• Moderate-to-severe obstructive sleep apnea → Zepbound gained an FDA indication for OSA in adults with obesity in December 2024.
• Chronic kidney disease → Ozempic added a CKD risk-reduction indication in 2025.

These non-weight-loss indications matter enormously: they give the plan — and, for older patients, Medicare — a covered reason to pay for a drug that is excluded when weight loss is the only stated purpose.

Why Insurers Deny GLP-1 Medications

Understanding the template language insurers use helps you dismantle their reasoning. Here are the five most common denial reasons:

1. BMI Does Not Meet Threshold

The denial states your BMI is below 30 (or below 27 if you have comorbidities), so the drug is "not medically necessary." Some plans require BMI ≥30 without exception, even when you have obesity-related diseases like prediabetes or hypertension.

2. Step Therapy Not Satisfied

The insurer requires you to try—and fail—older, cheaper weight-loss drugs first: typically phentermine/topiramate (Qsymia) or naltrexone/bupropion (Contrave), sometimes even an older GLP-1 like Saxenda before approving Wegovy or Zepbound.

3. No Documented Supervised Weight-Loss Program

Many policies require proof of a "6-month physician-supervised diet and exercise program" before covering any weight-loss medication. If your chart notes don't document monthly visits with weight logs, the claim is denied.

4. Plan Excludes Weight-Loss Drugs (Carve-Out)

Your employer's benefits agreement explicitly excludes "medications for the treatment of obesity" or "weight management drugs." This is common in self-insured employer plans and often appears as a blanket exclusion in your Summary Plan Description.

5. Cosmetic or Lifestyle Use

The denial letter claims the prescription is for "cosmetic purposes" or "lifestyle weight loss" rather than treatment of a chronic disease. This language is used when the diagnosis codes submitted don't clearly indicate obesity as a disease state or when comorbidities aren't documented.

---

The Citations Insurers Respect

Insurers write medical policies based on clinical guidelines, FDA labeling, and peer-reviewed trials. When you cite these sources in an appeal, you force the medical director reviewing your case to reconcile their denial with their own stated standards. Here are the key references:

Clinical Guidelines

• AACE 2023 Obesity Clinical Practice Guidelines: Defines obesity using the ABCD staging system (Adiposity-Based Chronic Disease). Supports pharmacotherapy for patients with BMI ≥25–27 when severe weight-related complications are present, not just BMI ≥30.

• AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults (2013, updated 2023): Recommends pharmacotherapy as an adjunct to lifestyle modification for patients with BMI ≥30 or BMI ≥27 with comorbidities. Updated 2023 guidance explicitly includes GLP-1 agonists as first-line options.

• Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity (2015): Recommends GLP-1 agonists for patients who have not achieved sufficient weight loss with lifestyle intervention alone.

• ADA Standards of Care in Diabetes (2025): Recommends semaglutide and tirzepatide for patients with type 2 diabetes and overweight/obesity to achieve glycemic control and weight reduction.

Landmark Trials

• STEP-1 (NEJM 2021): Semaglutide 2.4 mg (Wegovy) resulted in 14.9% mean weight loss vs. 2.4% with placebo at 68 weeks.

• STEP-2 (Lancet 2021): Semaglutide in patients with type 2 diabetes achieved 9.6% weight loss and significant HbA1c reduction.

• SURMOUNT-1 (NEJM 2022): Tirzepatide (Zepbound/Mounjaro) 15 mg resulted in 20.9% mean weight loss at 72 weeks.

• SURMOUNT-2 (Lancet 2023): Tirzepatide in patients with type 2 diabetes achieved 14.7% weight loss and improved cardiometabolic markers.

• SCALE Obesity and Prediabetes (NEJM 2015): Liraglutide 3.0 mg (Saxenda) resulted in 8.0% weight loss vs. 2.6% placebo.

• SELECT trial (NEJM 2023): Semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity, independent of weight loss.

When you cite these by name—especially the SELECT trial for cardiovascular benefit—you elevate the appeal from "I want to lose weight" to "this drug reduces my risk of heart attack and stroke."

---

How to Argue Against Each Denial Reason

Denial: BMI Does Not Meet Threshold

What the insurer says: "Patient's BMI is 28. Policy requires BMI ≥30 or BMI ≥27 with comorbidities. Request does not meet criteria."

Your counter-argument:

1. If you have weight-related comorbidities (type 2 diabetes, prediabetes, hypertension, sleep apnea, fatty liver, high cholesterol, PCOS, or cardiovascular disease), cite the AACE 2023 guidelines, which classify obesity as a disease using the ABCD system. Under this framework, a patient with BMI 27–29.9 and severe complications (stage 2 or 3 ABCD) qualifies for pharmacotherapy. List your comorbidities explicitly in the appeal and include ICD-10 codes: E66.01 (morbid obesity due to excess calories), E11.9 (type 2 diabetes), I10 (hypertension), G47.33 (obstructive sleep apnea), K76.0 (fatty liver).

2. If your BMI was higher when prescribed but has dropped due to initial success on the drug, state this clearly: "Patient's BMI was 32 at initiation; current BMI of 28 represents therapeutic response, not grounds for discontinuation."

3. If your insurer is UnitedHealthcare, Aetna, or Cigna, cite their own medical policies, which allow BMI ≥27 with at least one comorbidity. Attach a printout of the policy from their provider portal.

4. Ask your doctor to document functional impairment: joint pain limiting mobility, inability to perform work duties, decline in activities of daily living. The AHA/ACC/TOS 2023 guidelines support treatment when obesity impairs quality of life, even at lower BMI thresholds.

Denial: Step Therapy Not Satisfied

What the insurer says: "Patient must trial phentermine/topiramate or Contrave before GLP-1 agonist."

Your counter-argument:

1. Document contraindications. Phentermine is contraindicated in patients with cardiovascular disease (including uncontrolled hypertension, coronary artery disease, arrhythmia), hyperthyroidism, glaucoma, or use of MAO inhibitors within 14 days. Topiramate is contraindicated in patients with a history of kidney stones, glaucoma, or pregnancy risk (requires two forms of contraception). If any of these apply, your physician should state: "Phentermine/topiramate is contraindicated due to [specific condition]. Step therapy requirement poses unacceptable risk."

2. Argue clinical inferiority. Phentermine/topiramate produces 7–9% weight loss; Contrave produces 4–5% weight loss. Wegovy produces 14.9% (STEP-1), Zepbound up to 20.9% (SURMOUNT-1). If you need to lose significant weight to reverse prediabetes, reduce cardiovascular risk, or qualify for surgery, cite the Endocrine Society 2015 guideline, which states that the most effective agent should be chosen based on patient-specific factors, not cost alone.

3. If the insurer requires trying Saxenda before Wegovy or Zepbound, cite comparative efficacy: Saxenda produces 8% weight loss (SCALE trial) vs. 14.9% for Wegovy (STEP-1) and 20.9% for Zepbound (SURMOUNT-1). Argue that requiring a trial of a less effective agent delays achievement of therapeutic goals and exposes the patient to additional months of uncontrolled comorbidities.

4. State prior attempts clearly. Even if you didn't try phentermine specifically, if you tried supervised diet programs, metformin, or other medications and failed to achieve ≥5% weight loss, document this. The appeal should say: "Patient completed [specific program] from [date] to [date] without adequate response. Further delay with step-therapy agents is not in the patient's medical interest."

Denial: No Documented Supervised Weight-Loss Program

What the insurer says: "Policy requires 6-month physician-supervised diet and exercise program. Medical records do not document this."

Your counter-argument:

1. Ask your doctor to provide an addendum letter listing every clinical encounter in the past 6–12 months where weight, diet, or exercise was discussed. Even if visits weren't labeled "weight management," if your physician documented BMI, nutritional counseling, or activity recommendations at each visit, that counts. The letter should say: "Patient has been under my care since [date]. Weight management was addressed at visits on [list dates], including dietary counseling, activity recommendations, and BMI monitoring."

2. If you participated in a commercial program (Weight Watchers, Noom, a hospital-based program), submit proof: receipts, completion certificates, weight logs. The AHA/ACC/TOS 2013 guidelines define "comprehensive lifestyle intervention" as 14+ sessions over 6 months; many insurers accept structured programs even if not directly supervised by the prescribing physician.

3. If you have comorbidities that make delay dangerous, argue that further prolonging pharmacotherapy while you complete a 6-month program worsens outcomes. For example: "Patient has HbA1c of 7.8% and rising. Delaying GLP-1 therapy for an additional 6 months risks progression to insulin dependence. Weight management has been ongoing; an arbitrary documentation requirement should not override clinical urgency."

4. Cite the AACE 2023 guidelines, which state that pharmacotherapy should be initiated when lifestyle intervention alone is insufficient, not after a rigid 6-month waiting period if the patient has already demonstrated inadequate response to prior attempts.

Denial: Plan Excludes Weight-Loss Drugs

What the insurer says: "Your plan does not cover medications for weight management."

Your counter-argument:

This is the hardest denial to overturn, but not impossible:

1. If you have type 2 diabetes, ask your doctor to prescribe the diabetes-indicated formulation: Ozempic (semaglutide) or Mounjaro (tirzepatide) instead of Wegovy or Zepbound. These are FDA-approved for diabetes, not weight loss, and are usually covered under the pharmacy benefit's diabetes tier. The fact that they produce weight loss is a beneficial side effect, not the primary indication on the prescription.

2. If you have cardiovascular disease, cite the SELECT trial (NEJM 2023): semaglutide reduced MACE by 20% in patients with established CVD and overweight/obesity. Argue that the prescription is for cardiovascular risk reduction, not cosmetic weight loss. The denial of a cardioprotective medication constitutes an adverse benefit determination that your physician can appeal on cardiovascular grounds.

3. Request an exception for medical necessity. Even if the plan has a blanket exclusion, ERISA plans (most employer plans) must consider exceptions when denials would result in adverse health outcomes. Your physician should write: "Denial of this medication will result in continued progression of [diabetes, hypertension, sleep apnea], increased cardiovascular risk, and likely need for more costly interventions including bariatric surgery or insulin therapy. I request an exception based on medical necessity."

4. Check your state. Some states (e.g., Delaware, Maryland) have passed laws requiring insurers to cover obesity treatment, including medications, for policies issued in that state. If your state has such a law and your plan is fully insured (not self-funded), the exclusion may violate state law.

Denial: Cosmetic or Lifestyle Use

What the insurer says: "The requested medication is not covered for cosmetic weight loss."

Your counter-argument:

1. Ensure proper diagnosis coding. The claim must include ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity due to excess calories), plus codes for every comorbidity: E11.9 (type 2 diabetes), I10 (hypertension), E78.5 (hyperlipidemia), G47.33 (obstructive sleep apnea), K76.0 (fatty liver disease). If the original claim used only E66.9 (obesity, unspecified) or no comorbidity codes, resubmit with complete coding.

2. Have your physician write a letter stating: "This prescription is for the treatment of obesity, a chronic disease recognized by the AMA, CDC, and WHO, not for cosmetic purposes. The patient has [list comorbidities], which are directly caused or exacerbated by excess adiposity. The requested medication is medically necessary to prevent progression to insulin-dependent diabetes, cardiovascular events, and other serious complications."

3. Cite the AACE 2023 guidelines' ABCD framework, which classifies obesity by complications, not appearance. For example: "Patient has stage 2 ABCD obesity with moderate-to-severe complications (type 2 diabetes, hypertension). Treatment is essential to prevent stage 3 progression and end-organ damage."

4. If you've already lost weight on the medication and the insurer denies continuation, argue non-weight benefits: cite improvements in HbA1c, blood pressure, lipid panel, liver enzymes, or apnea-hypopnea index. The STEP-2 and SURMOUNT-2 trials show that GLP-1 agonists improve cardiometabolic markers independent of weight loss percentage.

---

If You Have Medicare

Medicare Part D is prohibited by statute from covering any drug "used for anorexia, weight loss, or weight gain" (Social Security Act §1927(d)(2)(A)). In April 2025, CMS confirmed it would not finalize a proposed rule to add anti-obesity coverage, so through 2025–2026 Part D still does not cover a GLP-1 prescribed solely for weight loss.

What Part D can cover is a GLP-1 prescribed for a separate, non-weight-loss FDA indication: the diabetes-labeled products (Ozempic, Mounjaro) for type 2 diabetes, Wegovy for cardiovascular risk reduction (its March 2024 indication), and Zepbound for obstructive sleep apnea (its December 2024 indication). On Medicare, the most productive appeal is almost always built on one of these covered indications rather than on weight loss.

(One narrow, temporary exception: CMS has announced a "Medicare GLP-1 Bridge" demonstration running July 2026 through December 2027 that offers select GLP-1s for weight reduction at a $50/month copay to eligible enrollees who meet BMI and qualifying-condition criteria. These rules are evolving — confirm the current details on Medicare.gov before relying on them.)

Medicare Part D appeals also follow a different, five-level process — plan redetermination, then an Independent Review Entity, an Administrative Law Judge, the Medicare Appeals Council, and finally federal court — not the commercial internal-appeal / external-review path below.

Your Appeal Rights and Deadlines

For commercial, ACA Marketplace, and most employer (ERISA) plans, federal rules give you a structured right to appeal a GLP-1 denial:

• Internal appeal: you have at least 180 days from the denial notice to file (29 CFR 2560.503-1; 45 CFR 147.136). Your prescriber or clinic can file as your authorized representative.
• Expedited appeal: when waiting could seriously jeopardize your health, the plan must decide within 72 hours.
• External review: after a final internal denial you have at least 4 months to request review by an Independent Review Organization — a neutral third party whose decision is binding on the insurer.

These rights are badly underused. Across ACA Marketplace plans in 2024, insurers denied about 19% of in-network claims, yet consumers appealed fewer than 1% of denials — and of the internal appeals that were filed, roughly a third were overturned (insurers upheld 66% in 2024 and 56% in 2023) (KFF, 2023–2024). A denial is the start of a process, not the end of one.

What We Do

We help patients turn denials into structured, evidence-based appeals. You upload your denial letter, answer a few questions about your health and what you've tried, and we generate a physician-ready appeal letter in under 60 seconds—citing the guidelines, trials, and policy language that peer reviewers must respect. Your doctor reviews, signs, and submits. No legal jargon, no delay, no hassle. Most appeals are decided within 30 days. The patients who never appeal — the overwhelming majority — leave the denial in place by default; a structured, well-cited appeal is what puts you among the cases that get overturned.

---

Sources

1. American Association of Clinical Endocrinology (AACE). Obesity Clinical Practice Guidelines, 2023.

2. American Heart Association / American College of Cardiology / The Obesity Society. Guideline for the Management of Overweight and Obesity in Adults, 2013; updated 2023.

3. Endocrine Society. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, 2015.

4. American Diabetes Association. Standards of Care in Diabetes, 2025.

5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021; 384:989–1002.

6. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2). Lancet 2021; 397:971–984.

7. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022; 387:205–216.

8. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023; 402:613–626.

9. Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med 2015; 373:11–22.

10. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023; 389:2221–2232.

11. Kaiser Family Foundation. Claims Denials and Appeals in ACA Marketplace Plans in 2023 (2025) and in 2024 (2026).

12. Kaiser Family Foundation. Coverage of GLP-1 drugs in ACA Marketplace plans, 2024 (Ozempic ~82% vs. Wegovy ~1%).

13. U.S. Food and Drug Administration. Wegovy (semaglutide) cardiovascular risk-reduction approval, March 2024; Zepbound (tirzepatide) obstructive sleep apnea approval, December 2024; Ozempic chronic kidney disease indication, 2025.

14. Centers for Medicare & Medicaid Services. Medicare Part D and anti-obesity medications — Contract Year 2026 final rule (April 2025); Medicare GLP-1 Bridge demonstration (2026).

15. 45 CFR 147.136 (internal appeals and external review); 29 CFR 2560.503-1 (ERISA claims procedure); Social Security Act §1927(d)(2)(A) (Part D weight-loss exclusion).